F-star develops novel bispecific antibodies directed at improving the treatment of serious diseases, with a focus in the area of immuno-oncology.

F-star designs and develops bispecific antibody products to improve the treatment of cancer.
F-star is the only biopharmaceutical company creating bispecific antibodies by modifying the constant region of an antibody. Our Modular Antibody Technology offers unprecedented ease in the development and manufacturing of genuine bispecific antibody products.

Modular Antibody Technology

Our robust discovery engine lets us easily “mix-and-match” antibody components to create unique bispecific antibody products.

Pipeline

F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as “2-in-1” drugs.